EMEA-001197-PIP01-11 - paediatric investigation plan

Ioforminol

Key facts

• Active Substance:
  Ioforminol
• Therapeutic area:
  Diagnostic
• Decision number:
  P/0222/2012
• PIP number:
  EMEA-001197-PIP01-11
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Visualisation of anatomical structures of the body during computed tomography for diagnostic purposes
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  GE Healthcare

  Norway; [e-mail]; Phone: [phone]; Fax: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  01/10/2012

Decision

P/0222/2012: EMA decision of 1 October 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for ioforminol (EMEA-001197-PIP01-11)

AdoptedReference Number: EMA/494333/2012